膀胱癌患者根治性膀胱切除术前使用18F-氟-2-脱氧-D-葡萄糖(18F-FDG)PET/CT评估淋巴结
基于199例2015至2022年间接受根治性膀胱切除及双侧盆腔淋巴结清扫的膀胱癌患者队列,评估术前18F-FDG PET/CT对淋巴结分期的诊断性能。术前PET/CT可疑淋巴结患者病理淋巴结转移率57%(17/30),阴性患者为23%(39/169);患者水平敏感度0.30、特异度0.91、阳性预测值0.57、阴性预测值0.77、准确率0.74。约八成术前PET/CT阴性患者最终病理证实为pN0。
要点
- 术前PET/CT阴性患者中约80%最终病理证实为pN0。
- 患者水平敏感度0.30、特异度0.91、阳性预测值0.57、阴性预测值0.77、准确率0.74。
- 新辅助化疗与免疫治疗亚组间未见差异。
核心结论
- 约八成术前18F-FDG PET/CT阴性的患者最终病理证实为pN0。
- 新辅助化疗与免疫治疗之间未发现差异。
- 这些发现提示18F-FDG PET/CT可能在膀胱癌患者淋巴结转移的术前评估中发挥作用,但其成本效益尚不确定。
研究设计与样本
- 基于199例2015至2022年间接受根治性膀胱切除及双侧盆腔淋巴结清扫的膀胱癌患者队列分析。
- 新辅助化疗或免疫治疗在肿瘤学评估后实施;所有患者术前接受18F-FDG PET/CT评估膀胱外病变。
- 计算常规影像与PET/CT的真阴性、假阴性、假阳性、真阳性、敏感度、特异度、阳性预测值、阴性预测值及准确率的点估计值,并对接受新辅助治疗的患者进行亚组分析。
主要发现
- 术前评估时,30例患者(15.1%)在18F-FDG PET/CT上有48个可疑淋巴结灶。
- 根治性膀胱切除及双侧盆腔淋巴结清扫共切除4871枚淋巴结,其中237枚淋巴结转移,对应126个不同区域。
- 术前PET/CT可疑与阴性的患者中,病理淋巴结转移分别为17/30(57%)与39/169(23%);敏感度0.30、特异度0.91、阳性预测值0.57、阴性预测值0.77、准确率0.74。
- 在纳入1367个淋巴结区域的按区域分析中,PET/CT可疑与阴性区域的淋巴结受累分别为19/48(39%)与105/1319(8%);敏感度0.15、特异度0.98、阳性预测值0.40、阴性预测值0.92、准确率0.90。
- 接受新辅助化疗(n=44,32.1%)与免疫治疗(n=93,67.9%)的患者中观察到相似结果:患者水平敏感度0.36、特异度0.91、阳性预测值0.59、阴性预测值0.80、准确率0.77;区域水平敏感度0.12、特异度0.98、阳性预测值0.32、阴性预测值0.93、准确率0.91。
局限性
- 研究局限性包括回顾性设计。
- 研究局限性包括患者数量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the diagnostic performance of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) positron emission tomograpy (PET)/computed tomography (CT) in nodal staging before radical cystectomy (RC) and pelvic lymph node dissection (PLND) for bladder cancer (BCa). MATERIALS AND METHODS: This analysis was based on a cohort of 199 BCa patients undergoing RC and bilateral PLND between 2015 and 2022. Neoadjuvant chemotherapy (NAC) or immunotherapy (NAI) was administered after oncological evaluation. All patients received preoperative 18F-FDG PET/CT to assess extravesical disease. Point estimates for true negative, false negative, false positive, true positive, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of conventional imaging and PET/CT were calculated. Subgroup analysis in patients receiving neoadjuvant treatment was performed. RESULTS: At preoperative evaluation, 30 patients (15.1%) had 48 suspicious nodal spots on 18F-FDG PET/CT. At RC and bilateral PLND, a total of 4871 lymph nodes (LNs) were removed with 237 node metastases corresponding to 126 different regions. Pathological node metastases were found in 17/30 (57%) vs 39/169 patients (23%) with suspicious vs negative preoperative 18F-FDG PET/CT, respectively (sensitivity = 0.30, specificity = 0.91, PPV = 0.57, NPV = 0.77, accuracy = 0.74). On per-region analysis including 1367 nodal regions, LN involvement was found in 19/48 (39%) vs 105/1319 (8%) suspicious vs negative regions at PET/CT, respectively (sensitivity = 0.15, specificity = 0.98, PPV = 0.40, NPV = 0.92, ACC = 0.90). Similar results were observed for patients receiving NAC (n = 44, 32.1%) and NAI (n = 93, 67.9% [per-patient: sensitivity = 0.36, specificity = 0.91, PPV = 0.59, NPV = 0.80, accuracy = 0.77; per-region: sensitivity = 0.12, specificity = 0.98, PPV = 0.32, NPV = 0.93, ACC = 0.91]). Study limitations include its retrospective design and limited patient numbers. CONCLUSIONS: In eight out of 10 patients with negative preoperative 18F-FDG PET/CT, pN0 disease was confirmed at final pathology. No differences were found based on NAC vs NAI treatment. These findings suggest that 18F-FDG PET/CT could play a role in the preoperative evaluation of nodal metastases in BCa patients, although its cost-effectiveness is uncertain.
引用
- Longoni M, Scilipoti P, Re C, et al. Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients. BJU Int. 2024. PMID: 38621771. doi:10.1111/bju.16363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。